TDMS No. 20310 - 02 **Test Type:** 26-39 WEEKS

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

3'-Azido-3'-deoxythymidine (AIDS) **CAS Number:** 30516-87-1

Date Report Requested: 07/22/2009 Time Report Requested: 11:51:18 First Dose M/F: 11/18/04 / NA

Lab: NCTR

Route: GAVAGE Species/Strain:

MICE/C3B6F1-+/Trp53(tm1Brd)

C Number: C20310C

Lock Date: 12/01/2008

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include 917 Vehicl PND 1-8 M Include 918 AZT 40 PND 1-8 M

Study Gender: Male

TDMSE Version: 2.1.0

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Test Type: 26-39 WEEKS

Route: GAVAGE Species/Strain:

MICE/C3B6F1-+/Trp53(tm1Brd)

3'-Azido-3'-deoxythymidine (AIDS) **CAS Number:** 30516-87-1

Date Report Requested: 07/22/2009 Time Report Requested: 11:51:18 First Dose M/F: 11/18/04 / NA

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicl PND 1-8 M	AZT 40 PND 1-8 M	
Disposition Summary			
Animals Initially in Study Early Deaths	24	25	
Natural Death Survivors		1	
Moribund Sacrifice Terminal Sacrifice	1 23	2 22	
Animals Examined Microscopically	24	25	
ALIMENTARY SYSTEM			
Intestine Large, Cecum Hyperplasia, Lymphoid	(24) 3 (13%)	(24) 1 (4%)	
Intestine Large, Rectum Degeneration, Cystic	(24) 1 (4%)	(24)	
Liver	(24)	(25)	
Cytomegaly Eosinophilic Focus	18 (75%)	14 (56%) 1 (4%)	
Inflammation, Chronic Active Necrosis	1 (4%) 2 (8%)	1 (4%) 1 (4%)	
Tension Lipidosis	3 (13%)	2 (8%)	
Vacuolization Cytoplasmic Pancreas	23 (96%) (23)	18 (72%) (25)	
Cytoplasmic Alteration Salivary Glands	1 (4%) (24)	(25)	
Infiltration Cellular, Lymphocyte	8 (33%)	8 (32%)	
CARDIOVASCULAR SYSTEM			
Blood Vessel Heart	(24) (24)	(24) (25)	
ENDOCRINE SYSTEM			
Adrenal Cortex	(24)	(25)	
Hypertrophy Subcapsular, Hyperplasia	7 (29%)	1 (4%) 7 (28%)	
Islets, Pancreatic Hyperplasia	(23) 1 (4%)	(25) 2 (8%)	
Thyroid Gland	(24)	(24)	

a - Number of animals examined microscopically at site and number of animals with lesion

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain:

MICE/C3B6F1-+/Trp53(tm1Brd)

3'-Azido-3'-deoxythymidine (AIDS) **CAS Number:** 30516-87-1

Date Report Requested: 07/22/2009 Time Report Requested: 11:51:18 First Dose M/F: 11/18/04 / NA

Lab: NCTR

a - Number of animals examined microscopically at site and number of animals with lesion

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Test Type: 26-39 WEEKS

3'-Azido-3'-deoxythymidine (AIDS)

Route: GAVAGE Species/Strain:

MICE/C3B6F1-+/Trp53(tm1Brd)

CAS Number: 30516-87-1 Lab: NCTR

First Dose M/F: 11/18/04 / NA

Date Report Requested: 07/22/2009

Time Report Requested: 11:51:18

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicl PND 1-8 M	AZT 40 PND 1-8 M
INTEGUMENTARY SYSTEM		
Skin	(24)	(25)
MUSCULOSKELETAL SYSTEM		
None		
NERVOUS SYSTEM		
Brain, Cerebrum	(24)	(25)
Mineralization	6 (25 [%])	3 (12%)
RESPIRATORY SYSTEM		
Lung	(24)	(25)
Foreign Body Infiltration Cellular, Polymorphonuclear		1 (4%) 1 (4%)
Bronchiole, Epithelium, Hyperplasia Nose	(24)	1 (4%) (25)
Foreign Body Inflammation, Suppurative	· /	1 (4%) 1 (4%)
		1 (470)
SPECIAL SENSES SYSTEM		
Harderian Gland	(24)	(25)
URINARY SYSTEM		
Kidney	(24)	(25)
Infiltration Cellular, Lymphocyte Mineralization	6 (25%)	6 (24%) 1 (4%)
Capsule, Inflammation, Chronic Active Pelvis, Dilatation	1 (4%)	1 (4%)
Renal Tubule, Regeneration	2 (8%)	3 (12%)
Urinary Bladder Infiltration Cellular, Lymphocyte	(24)	(24) 1 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a) 3'-Azido-3'-deoxythymidine (AIDS)

CAS Number: 30516-87-1

Date Report Requested: 07/22/2009

Time Report Requested: 11:51:18

First Dose M/F: 11/18/04 / NA

Lab: NCTR

Test Type: 26-39 WEEKS Route: GAVAGE

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE

Vehicl PND 1-8 M

AZT 40 PND 1-8 M

*** END OF MALE ***

*** END OF REPORT ***